26.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Moderna Inc Borsa (MRNA) Ultime notizie
SK bioscience wins patent case against Moderna in South Korea - Social News XYZ
TD Cowen Adjusts Moderna Price Target to $30 From $35, Maintains Hold Rating - marketscreener.com
Vaccine-wary Slovak PM pauses COVID-19 shot purchases pending review - marketscreener.com
Novavax says its COVID-19 shot is on track for full FDA approval after delay - Value The Markets
Moderna (NASDAQ:MRNA) Given Market Perform Rating at William Blair - MarketBeat
Canada Pension Plan Investment Board Raises Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
More Downside For Moderna Before The Breakthrough (NASDAQ:MRNA) - Seeking Alpha
Moderna Can't Buy Time To Defend COVID Vax UPC Claim - Law360
Press Release Distribution & PR Platform - ACCESS Newswire
Guggenheim Capital LLC Cuts Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Altshuler Shaham Ltd Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
What to Expect From Moderna's Q1 2025 Earnings Report - Nasdaq
Scotia Capital Inc. Has $284,000 Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Brokerages Set Moderna, Inc. (NASDAQ:MRNA) Target Price at $58.70 - MarketBeat
Bridgewater Associates LP Makes New Investment in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Wolfe Research Adjusts Moderna Price Target to $20 From $25, Keeps Underperform Rating - marketscreener.com
What To Expect From Moderna's Q1 2025 Earnings Report - Barchart.com
Preventive Vaccines Market Forecast 2025-2032- Growth - openPR.com
Where Will Moderna Be in 5 Years? - Yahoo Finance
Advisory Services Network LLC Purchases 16,555 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Q1 Earnings Forecast for Moderna Issued By Leerink Partnrs - MarketBeat
Lobbying Update: $60,000 of MODERNA INC. lobbying was just disclosed - Nasdaq
Russell Investments Group Ltd. Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Bank of Montreal Can Trims Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
The Gutierrez Co. Sued Over Mold, Water Damage at Moderna Site — Boston Business Journal - Boston Real Estate Times
Moderna sues construction firm claiming leaks, mold at new drug plant - NBC Boston
Water leaks, mold plague Moderna's new manufacturing site, lawsuit claims - The Business Journals
Quinn Opportunity Partners LLC Purchases Shares of 16,500 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Benzinga
Invesco Ltd. Acquires 979,858 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Says New Drug Plant Riddled With Defects, Mold - Law360
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Legal & General Group Plc - MarketBeat
Moderna (MRNA) Leads Healthcare Short Interest in March - GuruFocus
Lansdowne Partners UK LLP Acquires New Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Neuberger Berman Group LLC Reduces Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know - The Globe and Mail
Moderna permitted to start commercial mRNA vaccine manufacture in UK - The Pharma Letter
Leerink Partners Adjusts Moderna Price Target to $23 From $27, Maintains Underperform Rating - marketscreener.com
Moderna Co-Founder and MIT Legend Strengthens Decoy Therapeutics Drug Development Team - Stock Titan
MRNA Based Vaccines and Therapeutics Therapeutics Market Size - openPR.com
Renaissance Technologies LLC Grows Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
APG Asset Management N.V. Buys 203,792 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
FDA Special Assistant Høeg’s Vaccine Concerns On Display At ACIP - insights.citeline.com
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Shelton Capital Management - MarketBeat
Stocks Edge Up On Strong Bank Earnings, Netflix Soars, Dollar Rebounds: What's Driving Markets Tuesday? - Benzinga
Goldman Sachs Adjusts Moderna's Price Target to $35 From $49, Keeps Neutral Rating - MarketScreener
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):